摘要
目的:研究不同免疫状态下伊曲康唑治疗小鼠白念珠菌性阴道炎的疗效。方法:构建ICR小鼠白念珠菌性阴道炎模型,并应用地塞米松构建免疫抑制鼠模型;采用伊曲康唑灌服治疗;其中F组同时采用γ-IFN治疗,在灌药后不同时间动态观察阴道灌洗液真菌载量。结果:伊曲康唑治疗正常免疫组(A组)与对照组(D组)之间的疗效差异有显著性(P<0.01);免疫抑制组(E组)及免疫抑制后并进行免疫调节治疗组(F组)与对照组(G组)之间差异均有显著性(P<0.01);而A、E、F组在接种后的第5、6、7、9、11天其阴道灌洗液真菌载量无明显差异(P>0.05)。结论:伊曲康唑治疗不同免疫状况(即正常免疫、免疫抑制、免疫调节治疗状态下)的小鼠白念珠菌性阴道炎疗效均显著,而且正常免疫、免疫抑制及免疫增强状态下对伊曲康唑的抗真菌疗效无明显影响。
Objective： To determine the efficacy of itraconazole against vaginal candidiasis under different immune conditions in mice. Methods： ICR murine vaginal candidiasis models with normal immune system （group A） and dexamethasome- induced immunosuppressed （group E） were established. The mice were fed with fluid containing itraeonazole or IFN- γ. Results： The efficacy of itraconazole （A group） against vaginal candidiasis was higher than that of control group （P 〈 0.01 ）. The differences in efficacies between immunosuppressed group （group E）, immunoregulated group （group F） and control group were statistically significant （ P 〈 0.01 ）. There were no significant differences in average levels of colony forming unit （CFU） of group A, E, F at day 5, 6, 7, 9, 11 after inoculation （ P 〉 0.05）. Conclusion ： Itmconazole is effective in the treatment of vaginal candidiasis under different immune conditions （group A, E, F） in mice, with no significant difference in efficacy among the three groups.
出处
《中国麻风皮肤病杂志》
2007年第4期293-295,共3页
China Journal of Leprosy and Skin Diseases
基金
湖北省卫生厅科研基金资助项目(NO.JXIB048)
杨森科学研究基金项目
